Welcome to Nature’s Bioceuticals Online Store


Mistral Ventures Acquires One Hundred Percent Interest in Nature's Bioceuticals

CAPE CORAL, Fla., Oct. 20, 2011 /PRNewswire/ -- Mistral Ventures, Inc. (Pinksheets:MILV.pk - News) announced today that is has completed the acquisition of 100% of Nature’s Bioceuticals, Inc. Nature’s will operate as a wholly owned subsidiary of Mistral Ventures, Inc and is the first of many possible acquisitions in the rapidly expanding natural medicine market.
 
Nature’s Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature’s Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synthetic drugs and more importantly do not have the negative side effects usually associated with many of today’s prescribed drugs.
 
Nature’s line of Natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as "DSHEA" Safe Harbor Statement In addition to historical information, this release contains forward-looking statements. Mistral Ventures, Inc. and/or Nature’s Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures, Inc. and/or Nature’s Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as “expects,” “intends,” “believes,” “anticipates,” “should,” “likely,” and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Mistral Ventures, Inc. and/or Nature’s Bioceuticals assumes no obligation to update any forward-looking statement. Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company’s financial statements by the Company and its Audit Committee; modification of the Company’s accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC.
 
Media Contact: Rick Weiner
Phone Number: 561 200 7300
E-mail: info@naturesbioceutacles.com
www.naturesbioceuticals.com